ERBB2 and breast cancer: Given these clinical trial results, adjuvant neratinib was FDA-approved in 2017 for patients with HER2+ breast cancer who were previously treated with adjuvant trastuzumab for one year, and it is also administered in combination with capecitabine since 2020 for patients who received at least two previous anti-HER2 treatments [169,171].